Pharmaceutical and immunological evaluation of a single-shot hepatitis B vaccine formulated with PLGA microspheres.
A single-shot Hepatitis B vaccine formulation using poly(d,l)-lactide-co-glycolide acid (PLGA) microspheres as a delivery system was examined using a variety of biophysical and biochemical techniques as well as immunological evaluation in C3H mice. PLGA microsphere encapsulation of the Hepatitis B surface antigen (HBsAg), a lipoprotein particle, resulted in good recoveries of protein mass, protein particle conformational integrity, and in vitro antigenicity. Some partial delipidation of the HBsAg, however, was observed. The loading and encapsulation efficiency of HBsAg into the PLGA microspheres were measured along with the morphology and size distribution of the vaccine-loaded PLGA microspheres. The in vitro release kinetics of HBsAg from the PLGA microspheres was evaluated and found to be affected by experimental conditions such as stirring rate. HBsAg showed enhanced storage stability at 37 degrees C in the slightly acidic pH range reported to be found inside PLGA microspheres; thus, the antigen is relatively stable under conditions of temperature and pH that may mimic in vivo conditions. The immunogenicity of the microsphere formulations of HBsAg was compared with conventional aluminum adjuvant formulated HBsAg vaccine in C3H mice. Comparisons were made between aluminum formulations (one and two injections), PLGA microsphere formulations (single injection), and a mixture of aluminum and PLGA microsphere formulations (single injection). The nine-month serum antibody titers indicate that a single injection of a mixture of aluminum and PLGA-formulated HBsAg results in equal or better immune responses than two injections of aluminum-formulated HBsAg vaccine. Based on these in vitro and in vivo studies, it is concluded that HBsAg can be successfully encapsulated and recovered from the PLGA microspheres and a mixture of aluminum-adjuvanted and PLGA-formulated HBsAg can auto-boost an immune response in manner comparable to multiple injections of an aluminum-formulated vaccine.
Shi
Li
L
Department of Vaccine Pharmaceutical Research, Merck Research Laboratories, West Point, Pennsylvania 19486, USA. li_shi@merck.com
Caulfield
Michael J
MJ
Chern
Rey T
RT
Wilson
Roger A
RA
Sanyal
Gautam
G
Volkin
David B
DB
D000818:Animals; D001672:Biocompatible Materials / Q000493:pharmacokinetics; D002626:Chemistry, Pharmaceutical; D002942:Circular Dichroism; D003692:Delayed-Action Preparations; D004306:Dose-Response Relationship, Immunologic; D004353:Drug Evaluation, Preclinical; D004356:Drug Storage; D006514:Hepatitis B Surface Antigens / Q000008:administration & dosage / Q000737:chemistry / Q000276:immunology; D017325:Hepatitis B Vaccines / Q000276:immunology* / Q000493:pharmacokinetics*; D007115:Immunization Schedule; D007279:Injections, Subcutaneous; D019344:Lactic Acid / Q000737:chemistry / Q000276:immunology* / Q000493:pharmacokinetics*; D051379:Mice; D008809:Mice, Inbred C3H; D008863:Microspheres; D011100:Polyglycolic Acid / Q000737:chemistry / Q000493:pharmacokinetics*; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011108:Polymers / Q000737:chemistry / Q000493:pharmacokinetics*; D017550:Spectroscopy, Fourier Transform Infrared
D001672:Biocompatible Materials; D003692:Delayed-Action Preparations; D006514:Hepatitis B Surface Antigens; D017325:Hepatitis B Vaccines; D011108:Polymers; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid